{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:58:09Z","timestamp":1792699089477,"version":"4.5.0"},"reference-count":81,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>COVID-19 vaccines are possibly the most effective medical countermeasures to mitigate and ultimately bring to a halt the COVID-19 pandemic. As we transition to endemicity, inequitable access to vaccines, and particularly in low- and middle-income countries (LMICs), still poses risks of unprecedented disruptions and the emergence of viral mutations, which potentially lead to notorious vaccine-resistant variants. The missteps learned from the previous responses to the human immunodeficiency virus (HIV) and influenza outbreaks founded the hypothetical plan to ensure that vaccine accessibility to LMICs is not impeded. The SARS-CoV-2 vaccines\u2019 social promise was to lessen the underlying racial, ethnic, and geographic inequities that COVID-19 has both made apparent and intensified. Vaccine nationalism was evident throughout the COVID-19 crisis. Many high-income countries directly negotiated large advance orders for the vaccines, leaving resource-limited countries scrambling for access. This occurred despite international initiatives to structure the development and equitable distribution of vaccines, channeled through a vaccine pillar: COVID-19 Vaccines Global Access (COVAX). The serious supply shortages and national procurement methods of some countries that bypassed the vaccine pillar hindered the optimal function of COVAX in delivering timely and adequate doses to participating countries. COVAX strategized its approach by promoting fundraising, coordinating vaccine donations from countries with surplus doses, expediting reviews of vaccine candidates, and facilitating the expansion of the manufacturing capacity. While increasing capacity for production, technology transfer led to lesser siloes, enhanced manufacturing standardization, and less secrecy over production data. Ultracold storage requirements for leading vaccines were a considerable hurdle to the global immunization efforts, and particularly in LMICs with limited equipment and resources to support sophisticated cold-chain systems. Manufacturers strived to ease cold-chain restrictions on the basis of stability data submitted to national regulatory bodies. The development of single-dose vaccines offered promising solutions to simplify the administrative and logistic complexities that existed within the COVID-19 vaccination programs. As such, the requirements for both ultracold storage conditions were eased, and concerns over booster doses were addressed. To expand coverage, the dosing intervals of the Oxford\/AstraZeneca vaccines were extended according to data from Phase III clinical trials on effectiveness. In addition, with the recent outbreak of monkeypox, the lessons from past experiences of curbing infectious diseases, including COVID-19, must be learned and acted upon. The review summarizes the global efforts with respect to vaccine development, production, allocation, and deployment to achieve equitable access.<\/jats:p>","DOI":"10.3390\/vaccines10081306","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T03:40:32Z","timestamp":1660621232000},"page":"1306","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["The Race for Global Equitable Access to COVID-19 Vaccines"],"prefix":"10.3390","volume":"10","author":[{"given":"Lukman Nul Hakim","family":"Md Khairi","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, MARA, University of Technology (UiTM), Selangor Branch, Puncak Alam Campus, Puncak Alam 42300, Malaysia"},{"name":"Pharmacy Department, Hospital Sultanah Nur Zahirah, Ministry of Health Malaysia, Kuala Terengganu 20400, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-4290","authenticated-orcid":false,"given":"Mathumalar Loganathan","family":"Fahrni","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, MARA, University of Technology (UiTM), Selangor Branch, Puncak Alam Campus, Puncak Alam 42300, Malaysia"},{"name":"Collaborative Drug Discovery Research (CDDR) Group, Communities of Research (Pharmaceutical and Life Sciences), Universiti Teknologi MARA (UiTM), Puncak Alam 42300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8045-2346","authenticated-orcid":false,"given":"Antonio Ivan","family":"Lazzarino","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1NY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"ref_1","unstructured":"Ritchie, H., Orttiz-Ospina, E., Beltekian, D., Methieu, E., Hasell, J., Macdonald, B., Dattani, S., and Roser, M. (2022, July 01). Coronavirus (COVID-19) Vaccinations: Statistics and Research. Our World in Data. Available online: https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"576622","DOI":"10.3389\/fimmu.2020.576622","article-title":"The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens","volume":"11","author":"Duan","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-021-00323-6","article-title":"Access to and equitable distribution of COVID-19 vaccine in low-income countries","volume":"6","author":"Acharya","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration (FDA) (2022, August 03). Addressing New Variants: A Federal Perspective on the COVID-19 Response, Available online: https:\/\/www.fda.gov\/news-events\/congressional-testimony\/addressing-new-variants-federal-perspective-covid-19-response-01112022."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Peterson, C.J., Lee, B., and Nugent, K. (2022). COVID-19 Vaccination Hesitancy among Healthcare Workers\u2014A Review. Vaccines, 10.","DOI":"10.3390\/vaccines10060948"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/d41586-020-02774-8","article-title":"COVID-19 vaccines: How to ensure Africa has access","volume":"586","author":"Nkengasong","year":"2020","journal-title":"Nature"},{"key":"ref_8","unstructured":"Kaiser Family Foundation (2021, May 12). The U.S. President\u2019s Emergency Plan for AIDS Relief (PEPFAR). Available online: https:\/\/www.kff.org\/global-health-policy\/fact-sheet\/the-u-s-presidents-emergency-plan-for-aids-relief-pepfar\/."},{"key":"ref_9","unstructured":"The Global Fund (2021, May 12). HIV & AIDS\u2014The Global Fund to Fight AIDS, Tuberculosis and Malaria. Available online: https:\/\/www.theglobalfund.org\/en\/hivaids\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2307\/20034417","article-title":"The Next Pandemic","volume":"84","author":"Garrett","year":"2005","journal-title":"Foreign Aff."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3201\/eid1401.070700","article-title":"Influenza virus samples, international law, and global health diplomacy","volume":"14","author":"Fidler","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","unstructured":"Third World Network (2021, May 13). WHO: Negotiations to Continue on Influenza Virus and Benefit-Sharing. Available online: https:\/\/twn.my\/title2\/intellectual_property\/info.service\/2009\/twn.ipr.info.090507.htm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1016\/j.vaccine.2009.06.034","article-title":"Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza","volume":"27","author":"Collin","year":"2009","journal-title":"Vaccine"},{"key":"ref_14","unstructured":"Whalen, J. (2021, May 13). Rich Nations Lock in Flu Vaccine as Poor Ones Fret. Available online: https:\/\/www.wsj.com\/articles\/SB124243015022925551."},{"key":"ref_15","unstructured":"British Broadcasting Corporation (BBC) (2021, May 13). Poorer Nations Get Swine Flu Jabs. Available online: http:\/\/news.bbc.co.uk\/2\/hi\/health\/8302416.stm."},{"key":"ref_16","unstructured":"Global Preparedness Monitoring Board (GPMB) (2021, May 18). A World at Risk: Annual Report on Global Preparedness for Health Emergencies. Geneva. Available online: http:\/\/apps.who.int\/iris."},{"key":"ref_17","unstructured":"Weintraub, R., Bitton, A., and Rosenberd, M.L. (2021, May 21). The Danger of Vaccine Nationalism. Harvard Business Review. Available online: https:\/\/hbr.org\/2020\/05\/the-danger-of-vaccine-nationalism."},{"key":"ref_18","unstructured":"Marley, S. (2021, May 20). AstraZeneca Aims for 30 Million U.K. Vaccine Doses by September. Available online: https:\/\/www.bloomberg.com\/news\/articles\/2020-05-17\/astrazeneca-aims-for-30-million-u-k-vaccine-doses-by-september."},{"key":"ref_19","unstructured":"(2022, August 12). U.S. Secures 300 Million Doses of Potential AstraZeneca COVID-19 Vaccine. Available online: https:\/\/www.reuters.com\/article\/us-health-coronavirus-astrazeneca-idUSKBN22X0J9."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gayle, H., Foege, W., Brown, L., and Kahn, B. (2021, March 02). Framework for Equitable Allocation of COVID-19 Vaccine. Available online: https:\/\/doi.org\/10.17226\/25917.","DOI":"10.17226\/25917"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106774","DOI":"10.1016\/j.ijsu.2022.106774","article-title":"Monkeypox: Prioritizing public health through early intervention and treatment","volume":"104","author":"Fahrni","year":"2022","journal-title":"Int. J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106812","DOI":"10.1016\/j.ijsu.2022.106812","article-title":"Monkeypox outbreak: New zoonotic alert after the COVID-19 pandemic","volume":"104","author":"Sharma","year":"2022","journal-title":"Int. J. Surg."},{"key":"ref_23","unstructured":"World Health Organization (WHO) (2020). ACT-Accelerator Investment Case: Invest Now to Change the Course of the COVID-19 Pandemic, WHO."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"m4853","DOI":"10.1136\/bmj.m4853","article-title":"COVAX must go beyond proportional allocation of COVID vaccines to ensure fair and equitable access","volume":"372","author":"Herzog","year":"2021","journal-title":"BMJ"},{"key":"ref_25","unstructured":"Coalition for Epidemic Preparedness Innovations (CEPI) (2021, May 14). CEPI\u2019s Commitment to Tackling Racism. Available online: https:\/\/cepi.net\/about\/whoweare\/."},{"key":"ref_26","unstructured":"(2021, May 23). COVAX Publishes First Round of Allocations. Available online: https:\/\/www.gavi.org\/news\/media-room\/covax-publishes-first-round-allocations."},{"key":"ref_27","unstructured":"World Health Organization (WHO) (2020). WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination, WHO."},{"key":"ref_28","unstructured":"South China Morning Post (SCMP) (2021, May 21). In This Time of Crisis, Wealthy Nations Must Help the Less Fortunate, South China Morning Post, Available online: https:\/\/www.scmp.com\/comment\/opinion\/article\/3078675\/time-crisis-wealthy-nations-must-help-less-fortunate."},{"key":"ref_29","unstructured":"British Broadcasting Corporation (BBC) (2021, May 22). COVID-19 Vaccine: First Person Receives Pfizer Jab in UK. Available online: https:\/\/www.bbc.com\/news\/uk-55227325."},{"key":"ref_30","unstructured":"World Health Organization (WHO) (2021, May 22). Director-General\u2019s Opening Remarks at the Media Briefing on COVID-19\u20149 April 2021. Available online: https:\/\/www.who.int\/director-general\/speeches\/detail\/director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-9-april-2021."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kupferschmidt, K. (2021). Unprotected African Health Workers Die as Rich Countries Buy Up COVID-19 Vaccines, Science, American Association for the Advancement of Science (AAAS).","DOI":"10.1126\/science.abh1288"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"key":"ref_33","unstructured":"Duke University Health Innovation Center (2021, May 22). COVID-19; Launch and Scale Speedometer. Available online: https:\/\/launchandscalefaster.org\/COVID-19."},{"key":"ref_34","unstructured":"World Health Organization (WHO) (2021, May 23). COVAX Announces Additional Deals to Access Promising COVID-19 Vaccine Candidates; Plans Global Rollout Starting Q1 2021. Available online: https:\/\/www.who.int\/news\/item\/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021."},{"key":"ref_35","unstructured":"WHO Foundation (2021, May 23). Go Give One\u2014Vaccines for Everyone, Everywhere. Available online: https:\/\/gogiveone.org\/."},{"key":"ref_36","unstructured":"Haynes, E. (2021, May 23). Gates Aids Fundraising Drive for Global Vaccine Distribution, AP News, Available online: https:\/\/apnews.com\/article\/united-nations-coronavirus-health-business-8206b30e78b6011dc81a2a241d984537."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.21.287516","article-title":"COVAX and equitable access to COVID-19 vaccines","volume":"100","author":"Yoo","year":"2022","journal-title":"Bull World Health Organ."},{"key":"ref_38","unstructured":"World Health Organization (WHO), and United Nations Children\u2019s Fund (UNICEF) (2022, August 04). COVID-19 Vaccination: Supply and Logistics Guidance: Interim Guidance, 12 February 2021. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/339561."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ledford, H. (2021). J&J\u2019s single-dose COVID vaccine raises hopes for faster rollout. Nature.","DOI":"10.1038\/d41586-021-00526-w"},{"key":"ref_40","unstructured":"China Global Television Network (CGTN) (2021, May 25). Shanghai Starts Administering Single-Dose COVID-19 Vaccine. Available online: https:\/\/news.cgtn.com\/news\/2021-05-18\/Shanghai-starts-administering-single-dose-COVID-19-vaccine-10mVU5c6sGQ\/index.html."},{"key":"ref_41","unstructured":"China Global Television Network (CGTN) (2021, May 25). U.S. Greenlights Johnson & Johnson\u2019s Single-Dose COVID-19 Vaccine. CGTN. Available online: https:\/\/news.cgtn.com\/news\/2021-02-28\/U-S-greenlights-Johnson-Johnson-COVID-19-vaccine-YeVmfAXQDS\/index.html."},{"key":"ref_42","unstructured":"McGregor, G. (2021, May 25). China\u2019s Single-Dose COVID Vaccine Has Efficacy Similar to Johnson & Johnson\u2019s, Fortune, Available online: https:\/\/fortune.com\/2021\/02\/09\/china-covid-vaccine-single-dose-cansino-johnson-johnson\/."},{"key":"ref_43","unstructured":"U.S. Food and Drug Administration (FDA) (2022, August 04). Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers): Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19), Available online: https:\/\/www.fda.gov\/media\/146304\/download."},{"key":"ref_44","unstructured":"CanSino Biologics Inc (2022, August 04). Inside Information NMPA\u2019s Acceptance of Application for Conditional Marketing Authorization of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector). Available online: http:\/\/www.cansinotech.com\/upload\/1\/editor\/1614144655221.pdf."},{"key":"ref_45","unstructured":"Hall, B., Chazan, G., Mallet, V., and Dombey, D. (2021, May 26). Shortage of Coronavirus Shots Heaps Pressure on European Leaders, Financial Times, Available online: https:\/\/www.ft.com\/content\/fe851440-abcb-43e0-a7c9-a86a05d275db."},{"key":"ref_46","unstructured":"Newey, S., and Kelly-Linden, J. (2021, May 26). \u201cVery High\u201d Risk WHO-Led Vaccine Scheme Could Fail, Internal Documents Reveal. Available online: https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/high-risk-who-led-vaccine-scheme-could-fail-internal-documents\/."},{"key":"ref_47","unstructured":"Burrell, S. (2021). Should Vaccines Be Patent Protected in a Pandemic?, Frontier Economics. Available online: https:\/\/www.frontier-economics.com\/uk\/en\/news-and-articles\/articles\/article-i8200-should-vaccines-be-patent-protected-in-a-pandemic\/."},{"key":"ref_48","unstructured":"Rowland, C., and McGinley, L. (2021, May 26). Merck to Help Make Johnson & Johnson Coronavirus Vaccine, The Washington Post, Available online: https:\/\/www.washingtonpost.com\/health\/2021\/03\/02\/merck-johnson-and-johnson-covid-vaccine-partnership\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1126\/science.abc9588","article-title":"Knowledge transfer for large- scale vaccine manufacturing","volume":"369","author":"Rai","year":"2020","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40545-022-00411-5","article-title":"Management of COVID-19 vaccines cold chain logistics: A scoping review","volume":"15","author":"Fahrni","year":"2022","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_51","unstructured":"Gavi (2021, May 25). Cold Supply for Hot Demand. Available online: https:\/\/www.gavi.org\/vaccineswork\/cold-supply-hot-demand."},{"key":"ref_52","unstructured":"Gavi (2021, May 25). Gavi Board Calls for Global Access to COVID-19 Vaccines. Available online: https:\/\/www.gavi.org\/news\/media-room\/gavi-board-calls-global-access-covid-19-vaccines."},{"key":"ref_53","unstructured":"U.S. Food and Drug Administration (FDA) (2021, May 25). Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer."},{"key":"ref_54","unstructured":"Towfic, F. (2021, May 25). Pfizer COVID-19 Vaccine\u2019s Updated Cold Storage Requirements Will Get more Doses in more Arms, Pharmacy Times, Available online: https:\/\/www.pharmacytimes.com\/view\/pfizer-covid-19-vaccines-updated-cold-storage-requirements-will-get-more-doses-in-more-arms."},{"key":"ref_55","unstructured":"U.S. Food and Drug Administration (FDA) (2021, May 25). Letter granting Moderna EUA Amendment, Available online: https:\/\/fda.report\/media\/147284\/Moderna+Letter_Granting_EUA+Amendment_+final.pdf."},{"key":"ref_56","unstructured":"Huang, P. (2021, May 25). COVID-19 Vaccine Ethics: Is It Ever OK to Cut the Line? NPR. Available online: https:\/\/www.npr.org\/sections\/health-shots\/2021\/02\/06\/964139633\/is-it-ever-ok-to-jump-ahead-in-the-vaccine-line."},{"key":"ref_57","unstructured":"U.S. Food and Drug Administration (FDA) (2021, May 25). Coronavirus (COVID-19) Update: FDA Makes Two Revisions to Moderna COVID-19 Vaccine Emergency Use Authorization to Help Increase The Number Of Vaccine Doses Available, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-makes-two-revisions-moderna-covid-19-vaccine-emergency-use."},{"key":"ref_58","unstructured":"U.S. Food and Drug Administration (FDA) (2022, July 09). Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers): Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19), Available online: https:\/\/www.fda.gov\/media\/157233\/download."},{"key":"ref_59","unstructured":"U.K. Medicines & Healthcare Products Regulatory Agency (2022, July 10). Summary of Product Characteristics for Vaxzevria\u2014GOV.UK, Available online: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-astrazeneca\/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca."},{"key":"ref_60","unstructured":"CanSino Biologics Inc (2022, July 10). Package Insert for Convidecia (Trade Mark) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Solution for Injection, Available online: https:\/\/quest3plus.bpfk.gov.my\/front-end\/attachment\/130370\/pharma\/540015\/V_57634_20210831_123151_D3.pdf."},{"key":"ref_61","unstructured":"U.S. Food and Drug Administration (FDA) (2022, July 09). Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers): Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) for through 11 Years of Age, Available online: https:\/\/www.fda.gov\/media\/153714\/download."},{"key":"ref_62","unstructured":"U.S. Food and Drug Administration (FDA) (2022, July 09). Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers): Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) for 12 Years of Age and Older (Purple Cap), Available online: https:\/\/www.fda.gov\/media\/153713\/download."},{"key":"ref_63","unstructured":"U.S. Food and Drug Administration (FDA) (2022, July 09). Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers): Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) for 12 Years of Age and Older (Gray Cap), Available online: https:\/\/www.fda.gov\/media\/153715\/download."},{"key":"ref_64","unstructured":"Organisation for Economic Co-Operation and Development (OECD) (2021, May 26). Access to COVID-19 Vaccines: Global Approaches in a Global Crisis. Available online: https:\/\/www.oecd.org\/coronavirus\/policy-responses\/access-to-covid-19-vaccines-global-approaches-in-a-global-crisis-c6a18370\/#boxsection-d1e848."},{"key":"ref_65","unstructured":"Adam, A. (2021, May 26). Khairy: Second Dose of AstraZeneca COVID-19 Vaccine Interval Set for 12 Weeks after First Jab|Malaysia|Malay Mail. Available online: https:\/\/www.malaymail.com\/news\/malaysia\/2021\/05\/04\/khairy-second-dose-of-astrazeneca-covid-19-vaccine-interval-set-for-12-week\/1971489."},{"key":"ref_66","unstructured":"Raghavan, P. (2021, May 26). Explained: Why Has the Interval between Covishield Vaccine Doses Been Raised to 8 Weeks?, The Indian Express, Available online: https:\/\/indianexpress.com\/article\/explained\/why-interval-between-covishield-doses-has-been-raised-to-8-weeks-7240465\/."},{"key":"ref_67","unstructured":"Joint Committee on Vaccination and Immunisation (JCVI) (2021, May 26). Optimising the COVID-19 Vaccination Programme for Maximum Short-Term Impact. Available online: https:\/\/app.box.com\/s\/uwwn2dv4o2d0ena726gf4403f3p2acnu."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bernal, J.L., Andrews, N., Gower, C., Stowe, J., Tessier, E., Simmons, R., and Ramsay, M. (2021). Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. medRxiv.","DOI":"10.1101\/2021.05.14.21257218"},{"key":"ref_69","unstructured":"Ismail, S.A., Vilaplana, T.G., Elgohari, S., Stowe, J., Tessier, E., Andrews, N., Vusirikala, A., Ramsay, M., Mandal, S., and Berna, J.L. (2021, May 26). Effectiveness of BNT162b2 mRNA and ChAdOx1 adenovirus vector COVID-19 vaccines on risk of hospitalisation among older adults in England: An observational study using surveillance data. medRxiv, Available online: https:\/\/khub.net\/documents\/135939561\/430986542\/Effectiveness+of+BNT162b2+mRNA+and+ChAdOx1+adenovirus+vector+COVID-19+vaccines+on+risk+of+hospitalisation+among+older+adults+in+England.pdf\/9e18c525-dde6-5ee4-1537-91427798686b."},{"key":"ref_70","unstructured":"Public Health England (2021). Public Health England Vaccine Effectiveness Report: March 2021."},{"key":"ref_71","unstructured":"World Health Organization (WHO) (2022, August 04). Interim Recommendations for Use of the ChAdOx1-S [Recombinant] Vaccine Against COVID-19 (AstraZeneca COVID-19 Vaccine AZD1222, SII Covishield, SK Bioscience). Available online: https:\/\/www.who.int\/publications\/i\/item\/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/idr14040057","article-title":"Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review","volume":"14","author":"Garg","year":"2022","journal-title":"Infect. Dis. Rep."},{"key":"ref_73","unstructured":"Atmar, R.L., Lyke, K.E., Deming, M.E., Jackson, L.A., Branche, A.R., El Sahly, H.M., Rostad, C.A., Martin, J.M., Johnston, C., and Rupp, R.E. (2021). Heterologous SARS-CoV-2 Booster Vaccinations\u2014Preliminary Report. medRxiv, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/34671773\/."},{"key":"ref_74","first-page":"100249","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study","volume":"11","author":"Ballin","year":"2021","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_75","unstructured":"Centers for Disease Control and Prevention (CDC) (2022, August 04). DMID 21-0012\u2014Heterologous Platform Boost Study: Mix and Match, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/110917."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3389\/fmed.2021.783982","article-title":"Systematic Review and Meta-Analysis of COVID-19 Vaccination Acceptance","volume":"8","author":"Norhayati","year":"2022","journal-title":"Front. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-020-1124-9","article-title":"A global survey of potential acceptance of a COVID-19 vaccine","volume":"27","author":"Lazarus","year":"2020","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries","volume":"27","author":"Warren","year":"2021","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"m3320","DOI":"10.1136\/bmj.m3320","article-title":"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis","volume":"370","author":"Allotey","year":"2020","journal-title":"BMJ"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1306\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:07:56Z","timestamp":1760141276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081306"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081306","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}